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Abstract
Protective antigen (PA) is the primary protein antigenic component of both the currently used
anthrax vaccine and related recombinant vaccines under development. An analogue of
recombinant PA (2-FHis rPA) has been recently shown to block the key steps of pore formation in
the process of inducing cytotoxicity in cells, and thus can potentially be used as an antitoxin or a
vaccine. This rPA analogue was produced by fermentation to incorporate the unnatural amino acid
2-fluorohistidine (2-FHis). In this study, the effects of 2-FHis labeling on rPA antigen’s
conformational stability and dynamic properties were investigated by various biophysical
techniques. Temperature/pH stability profiles of rPA and 2-FHis rPA were analyzed by the
empirical phase diagram (EPD) approach, and physical stability differences between them were
identified. Results showed that rPA and 2-FHis rPA had similar stability at pH 7–8. With
decreasing solution pH, however, 2-FHis rPA was found to be more stable. Dynamic sensitive
measurements of the two proteins at pH 5 found that 2-FHis rPA was more dynamic and/or
differentially hydrated under acidic pH conditions. The biophysical characterization and stability
data provide information useful for the potential development of 2-FHis rPA as a more stable rPA
vaccine candidate.
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INTRODUCTION
Anthrax, a lethal disease caused by spores of the Gram-positive bacterium Bacillus
anthracis, attacks mammalian hosts by cutaneous, inhalation and gastrointestinal routes.
Mortality from anthrax disease is high in untreated cases and varies by infective routes. The
inhaled form of the disease is the most severe and results from the inhalation of airborne
spores. The mortality in untreated inhalational anthrax cases is almost 100%.1 There are
recent serious concerns about the inhaled form due to its potential use as a biological
weapon.2 Therefore, major efforts have involved the development of effective anthrax
countermeasures such as vaccines.
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Protective antigen (PA) is nontoxic by itself but essential for the toxic activity of Bacillus
anthracis, the causative agent of anthrax. PA is an 83 kDa, four domain multifunctional
protein which is recognized by anthrax toxin receptors 1 and 2 on host cells.3,4 Following
receptor binding, PA is cleaved by a furin-like protease to yield a 63 kDa fragment (PA63)
and an N-terminal 20 kDa fragment (PA20).5 Cleaved PA63 assembles on the surface of cells
into a heptameric6 or octameric7 donut-shaped structure called a prepore. The prepore
subsequently combines with edema factor (EF) and lethal factor (LF) to create a number of
different, but functionally similar, complex toxins such as edema toxin (EdTx) and lethal
toxin (LeTx). After receptor-mediated endocytosis, and a subsequent conformational change
in PA from a prepore to a pore in acidified endosomes (pH 5~6), actively toxic proteins EF
and LF can be translocated through the pore into the cytoplasm of target cells, which results
in cellular toxicity causing cell killing and host death.5,8,9,10 Since PA plays an important
role in the pathology of anthrax, yet is a non-toxic and a strongly immunogenic molecule, it
is used as a primary antigen in anthrax vaccines.
PA is the protein antigen component in the currently used vaccine and provides a certain
level of protective immunity against anthrax infection. The licensed U.S. anthrax vaccine
(AVA, BioThrax) contains predominantly protective antigen adsorbed to aluminum
hydroxide. It is an effective vaccine for the protection of humans anthrax5, however, there
are limitations of the current AVA vaccine. The AVA vaccine has limited duration of
protection, and 6 doses are required over 18 months followed by annual boosters.11 The
AVA is composed of PA and an incompletely defined culture supernatant adsorbed to the
adjuvant, so the vaccine purity is not easily determined. Therefore, there is a need to develop
newer versions of vaccines such as those based on recombinant PA, which have more
defined composition and can produce the long-lasting immunity.
A novel recombinant protein analogue of PA, designated 2-fluorohisidine recombinant
protective antigen (2-FHis rPA), was recently found to have the capability to block the key
step of pore formation.12,13 The preparation of the 2-FHis rPA analogue was achieved by
incorporation of the unnatural amino acid 2-fluorohisidine, an isosteric analogue of histidine
with a significantly reduced pKa(~1)14, during fermentation resulting in ten histidine
residues in rPA being biosynthetically replaced by 2-fluorohistidine. The protein was
structurally similar to the WT protein as determined by X-ray crystallography13, but this
replacement was found to block low pH-induced pore formation with cells and thus
protected from the lethal effects of the toxin.12,13 These results suggested that 2-FHis rPA
might potentially be used as an antitoxin or a vaccine to treat anthrax infections.
We have therefore examined the effect of 2-fluorohistidine labeling of rPA on its stability
and dynamics to further explore its potential use as a therapeutic entity. The conformational
stability and dynamic properties of rPA and 2-FHis rPA were evaluated and compared as a
function of solution pH and temperature. The physical stability of the two proteins was
investigated as a function of pH (4–8) and temperature (10–85°C) using various biophysical
techniques. Near and far UV circular dichroism, intrinsic and extrinsic fluorescence as well
as light-scattering optical density data were collected and empirical phase diagrams were
constructed to summarize the large volume of the data collected. The physical stability
profiles were then compared to distinguish stability differences between the two proteins.
Based on the biophysical characterization results, the dynamic properties of the two proteins
at pH 5 were then studied to better understand the difference in thermal stability observed
between the two proteins at pH 5. The dynamic properties of proteins were investigated by
red-edge excitation shifts and high resolution ultrasonic spectroscopy.
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Recombinant protective antigen (rPA) and its 2-fluorohistidine labeled analogue (2-FHis
rPA) were produced by the Laboratory of Bioorganic Chemistry at Wichita State University
(Wichita, KS) as liquid solutions (~20 mg/ml) in 20 mM Tris buffer containing 150 mM
NaCl at pH 8. Expression, production, and purification of rPA and 2-FHis rPA were carried
out as described previously.14 All other reagents including buffers and salts were purchased
from Sigma-Aldrich (St. Louis, MO).
For the physical characterization studies, high concentrations of stock protein samples (~ 20
mg/ml) were freshly prepared by dilution into 20 mM citrate phosphate buffer with an ionic
strength of 0.15 (adjusted with sodium chloride) ranging from pH 4 to 8, at one pH unit
intervals. The final experimental protein concentration was 0.5 mg/ml.
For dynamic studies, high concentrations of stock protein samples were freshly diluted to
approximately 1.5 mg/ml using 20 mM Tris buffer containing 150 mM NaCl at pH 8.
Diluted samples were then dialyzed in 20 mM citrate phosphate buffer at pH 5 at 4°C using
Slide-A-Lyzer dialysis cassettes (Thermo Scientific, Rockford, IL) with a 3.5 kDa MW
cutoff. The pH value of 5 for the working buffer was determined from the biophysical
characterization results. Protein concentration was 0.5 mg/ml for red-edge excitation shifts
experiments, and was 0.9 mg/ml for both density and high resolution ultrasonic
spectroscopy measurements.
Biophysical Characterization
Far and Near UV Circular Dichroism Spectroscopy—Circular dichroism analysis
was performed with a Chirascan-plus Circular Dichroism Spectrometer (Applied
Photophysics Ltd, Leatherhead UK) equipped with a Peltier temperature controller and a 4-
position cuvette holder. Far and near UV spectra of samples (0.5 mg/ml) were collected
simultaneously in the range of 200–360 nm using a 0.2 cm path length cuvette.15 The step
size of spectra scanning was 1 nm. A sampling time per point of 3 s and a bandwidth of 1
nm were used. The characteristic CD signals of proteins (pH 4–8) at 220, 262, 269, 284 and
291 nm observed in the near and far UV CD regions were monitored as a function of
temperature from 10 to 85°C at 2.5°C intervals. Triplicate measurements were made, and the
equilibration time at each temperature was 1 minute.
Optical Density Measurements—Ultraviolet absorbance measurements were made
simultaneously during the near and far UV CD experiments using the same experimental
parameters.15 The aggregation behavior of rPA and 2-FHis rPA (0.5 mg/ml) was monitored
by recording the optical density at 350 nm as a function of temperature (10–85°C) and pH
(4–8).
Intrinsic Fluorescence Spectroscopy—In a series of separate experiments,
fluorescence emission scan data were also collected on the Chirascan-plus instrument by
using an attached fluorescence detector. A 2 × 10 mm quartz cuvette was used in all
experiments, and excitation of the proteins was carried out along the shorter path length (2
mm). Fluorescence emission spectra of the two proteins (0.5 mg/ml) were recorded using the
same temperature program as used previously. Triplicate samples were measured using an
excitation wavelength of 295 nm (> 95% tryptophan emission). Emission spectra were
collected from 305 to 395 nm with a step size of 1 nm and 2 s sampling time per point. The
excitation and emission slits were set at 4 and 9 nm, respectively. The position of the
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emission wavelength maximum was determined using a polynomial derivative fitting
method executed in Origin 7.0 software.
Extrinsic (ANS) Fluorescence Spectroscopy—8-Anilino-1-naphthalene sulfonate
(ANS) was used as an extrinsic probe to study conformational changes of the two proteins
that result in changes in its surface polarity. The interaction of ANS with the apolar surfaces
of rPA and 2-FHis rPA were monitored as a function of temperature (10–85°C) and pH (4–
8) using a QuantaMaster Spectrophotometer (Photon Technology International (PTI), Inc.,
Birmingham, NJ). Each sample solution (0.5 mg/ml) containing 89 µM diluted ANS (a
molar ratio of the ANS to the protein of 15:1) was incubated at 10°C in the dark for 20
minutes before measurement. Samples were excited at 375 nm and spectra were collected
from 400 to 600 nm at 2.5°C intervals, with a 3 min equilibration time at each temperature.
Duplicate measurements were made using a 2 mm path length quartz cuvette to check for
inner filter effects (none were seen). Buffer baselines containing ANS were subtracted from
each sample spectrum prior to analysis. Peak positions and intensities of the emission
spectra were obtained using a polynomial derivative fitting method as described above
(Section: Intrinsic Fluorescence Spectroscopy).
Empirical Phase Diagram (EPD)—The empirical phase diagram (EPD) was constructed
as described previously16,17 to summarize and facilitate the analysis of the complex
biophysical data sets obtained. The EPD is used to identify coherent parameter regions that
define protein structural states as a function of solution variables (temperature and pH in this
case). CD signals at 220, 262, 269, 284 and 291 nm, optical density, intrinsic Trp
fluorescence peak positions, and extrinsic fluorescence intensities data were used for
construction of the EPDs of rPA and 2-FHis rPA. All calculations were performed using
Matlab software (MathWorks, Natick, MA).
Dynamic Properties Measurements
High Resolution Ultrasonic Spectroscopy—Ultrasonic spectroscopy measurements
were performed using an HR-US 102 Spectrometer (Ultrasonic Scientific, Dublin, Ireland)
with a frequency range of 2–18 MHz and a resolution of 0.2 mm/s for velocity and 0.2% for
attenuation measurements. The differential velocity and attenuation between sample and
reference cells were monitored at 12 MHz from 10 to 85°C and pH 5. The sample and
reference solutions (0.9 mg/ml) were thoroughly degassed before each measurement. The
sample and reference cells contained 1 ml of protein and buffer solution, respectively. The
temperature of the cells was controlled by a Phoenix P2 water circulator (Thermo Haake,
Newington, NH). Data were analyzed using HRUS v4.50.27.25 software. The coefficient of
adiabatic compressibility (βs) was determined using the equations described previously.18
The adiabatic compressibility of the sample and buffer are related to the density (ρ) and
ultrasonic velocity (u) by the Laplace equation, β=1/ρu2.
Density—The densities of the two protein solutions (0.9 mg/ml) and corresponding buffer
solutions were measured using a DMA-5000 high precision densitometer (Anton Paar, Graz,
Austria) at a precision of 1 ×10−6 g/cm3 and ±0.001°C. The densities of degassed solutions
were measured from 5–22°C and 5–32°C for rPA and 2-FHis rPA in their unfolding pre-
transition ranges, respectively. The increment of the temperature was 1°C. The instrument
was calibrated with dry air and degassed water before analysis.
Red-Edge Excitation Shifts—Fluorescence measurements used in the determination of
red-edge excitation shifts were performed with the PTI QuantaMaster Spectrophotometer.
Protein concentration was 0.5 mg/ml. Excitation wavelengths of 292, 296, 300 and 304 nm
were used, and the emission spectra were collected from 300 to 400 nm. The excitation and
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emission slit widths were set to 2 nm. The data were collected from 10 to 50°C in 2°C
increments with a 3 minutes equilibration time. Triplicate measurements were made using a
2 mm path length quartz cuvette. The relative change in peak position was determined using
a mean spectral center of mass (MSM) method spanning the emission spectra range of 310
to 400 nm. This range of data analysis and the lower pathlength employed for fluorescence
measurements (2 mm) should minimize the contribution of Rayleigh scattering even when
the data is collected at 304 nm (the highest excitation wavelength employed) as well as the
lower excitation wavelengths used in these studies. The mean spectral center of mass
method is a peak picking algorithm to determine the peak maximum. The maximum peak
position is based on the center-of mass position of the area in a selected peak integration
region (from 310- 400 nm in this case).The peak position maxima obtained by the MSM
method are generally ~8–10 nm higher than the actual peak position obtained by derivative
analysis but result in a better signal to noise ratio.
RESULTS
Biophysical Characterization
Near and Far UV Circular Dichroism Spectroscopy—Near and far UV CD spectra
of 0.5 mg/ml rPA and 2-FHis rPA at pH 7 and 10°C are shown in Figure 1. In the far- UV
region (200–250 nm), both proteins display a broad peak with a minimum at around 210 nm
and a shoulder at 220 nm, suggesting that proteins contain a mixture of α-helix and β-sheet
structures. In the near-UV region (250–320 nm), four characteristic peaks at 262, 269, 284
and 291 nm were observed, presumably due to the aromatic amino acid side chains.19,20
The effect of temperature on the two protein’s secondary and tertiary structures was further
investigated by using thermal melt analysis. CD signals at five characteristic peaks (220,
262, 269, 284 and 291 nm) were monitored across the pH range of 4–8. Typical thermal
unfolding curves of 2-FHis rPA and rPA at pH 7 are shown in Figure 2 and Supplemental
Figure S1, respectively, with triplicate measurements resulting in good reproducibility. The
rPA and 2-FHis rPA proteins show similar pattern in their CD thermal unfolding curves
across the entire pH range examined. Although an overall loss in secondary and tertiary
structures is observed as a function of increasing temperature for both proteins, the thermal
transition midpoint (Tm) values vary greatly between the two proteins as the pH value
decreases. For example, the two proteins show a significantly lower thermal stability at pH 5
(Supplemental Figures S2 and S3). The Tm values from CD thermal melt curves were
calculated for both proteins and results are summarized in Table 1. The two proteins show
similar conformational stability at pH 7 and 8. Differences in thermal stability between the
two proteins are, however, observed at pH 5 and 6 (see Table 1), especially at pH 5.
Interestingly, the Tm value for 2-FHis rPA at pH 5 evaluated from the Far-UV CD data was
greater than that obtained from the near-UV CD data, suggesting that a molten globule like
state exists in the temperature range from 35 – 41 °C. Molten globules generally possess
native-like secondary structure but lack significant tertiary structure. This is seen as a
gradual color change region in the EPDs. While the Tm values for both proteins decrease as
a function of pH, the 2-FHis rPA exhibits a slightly higher thermal stability than rPA at pH
6, and the analogue rPA has significantly higher stability than rPA at pH 5 with an increased
Tm value of approximately 10°C.
Intrinsic Fluorescence Spectroscopy—Alternations in tertiary structure as a function
of temperature and solution pH of the two rPA proteins were also investigated by intrinsic
fluorescence spectroscopy. Figures 3A and B show the changes in the position of the
emission peak maximum and structural changes occurred in both proteins but at different
temperatures depending on pH. rPA and 2-FHis rPA show their highest thermal stability at
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pH 7–8 and 6–8, respectively. The stability of rPA decreases much more dramatically
compared to 2-FHis rPA between pH 4 and 6 (see Table 1 for the calculated Tm values). At
pH 7 and 8, both proteins show comparable structural integrity with initial peak positions of
about 329 nm at low temperatures. With increasing temperature, the emission peak
maximum shifts to about 342 nm, indicating the proteins were conformationally altered but
not completely unfolded at elevated temperatures. In summary, both proteins show their
highest thermal stability at pH 7 and 8, and manifest lower thermal stability with decreasing
pH.
Optical Density Measurements—Optical density (OD) data at 350 nm were collected
simultaneously during CD measurements. rPA and 2-FHis rPA both manifested aggregation
as measured by increases in OD values with increasing temperature (Figures 3C and D). The
temperature dependent OD changes (i.e., protein aggregation) are overall consistent with the
observations made from the CD and intrinsic fluorescence measurements, with similar
trends of pH and temperature. Again, 2-FHis rPA was significantly more stable than rPA at
pH 5, where the midpoint of the aggregation values for rPA and 2-FHis rPA were 39.0°C
and 28.5°C, respectively. Interestingly, the 2-FHis rPA analogue is actually more stable at
pH 5 than at pH 4, in contrast to the recombinant rPA protein.
Extrinsic (ANS) Fluorescence Spectroscopy—ANS (8-Anilino-1-naphthalene
sulfonate) is a fluorescent dye that binds to apolar regions in proteins, resulting in large
increases in fluorescence quantum yield and a blue shift in peak position.21 This observation
must always be qualified, however, by the possibility of electrostatic interactions of the
negatively charged dye with a protein. Figure 4 shows the thermal melting curves of the two
proteins at various pH values. These curves were obtained by monitoring the ANS emission
peak intensity as a function of temperature. At pH 4, ANS data for rPA show significant
fluorescence intensity even at low temperatures (Figure 4A). This increased fluorescence
intensity is presumably induced by the binding of ANS to the structurally altered rPA
protein under acidic conditions. Increased ANS fluorescence intensity with increases in
temperature is observed over the pH range of 4 to 8. The Tm values for these transitions are
summarized in Table 1. In agreement with results obtained from other biophysical
techniques, both proteins show their greatest structural stability at pH 7–8. At pH 6, 2-FHis
rPA is slightly more stable than rPA. Again, at pH 5, the maximum difference in the stability
of two proteins is observed.
Empirical Phase Diagrams (EPDs)—Empirical phase diagrams (EPDs) are used to
summarize large amounts of data to provide a more comprehensive view of the stability
profiles of proteins. Such diagrams should not be confused with thermodynamic phase
diagrams, however, since no equilibrium between phases is implied. The EPDs of rPA and
2-FHis rPA generated from all of the collected data are shown in Figures 5A and B,
respectively. Overall, the EPD of the rPA protein (Figure 5A) shows similar defined
“apparent” phases compared to those in the EPD of 2-FHis rPA (Figure 5B). There are two
major phases seen for both proteins. In region 1, both proteins at pH 5–8 show a similar
color below about 48°C, suggesting that they exist in similar structural states. By examining
the data obtained from the specific techniques, region 1 at low temperatures from pH 5–8 is
presumably the native state of protein. rPA and 2-FHis rPA show similar apparent phase
boundaries across the pH range 6 to 8. In contrast, rPA shows lower stability than 2-FHis
rPA at pH 6 as evidenced by a decreased Tm value of about 2.5°C (Table 1). At pH 5, there
is a much more significant thermal stability difference between the two proteins. Both the
EPDs and the individual experimental methods all show that 2-FHis rPA has much greater
thermal stability (Tm value difference of 10–12°C). Unlike the EPD of 2-FHis rPA, the EPD
of rPA displays an additional region (Region 2 in Figure 5A) based on phase color changes.
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In region 2, rPA samples at pH 4 show a distinct color (green) difference from region 1. This
observation clearly arises from results obtained from extrinsic (ANS) fluorescence data. As
discussed previously, at pH 4, rPA with ANS shows significant fluorescence intensity even
at low temperature (Figure 4A), suggesting the binding of ANS to a partially unfolded
protein at this acidic condition. At high temperatures, both proteins are structurally altered
and aggregate as indicated by the presence of region 3. From the EPDs, we can see that the
most stable region of two proteins is in the pH range of 7 to 8.
Dynamic Properties
High Resolution Ultrasonic Spectroscopy—HR-US spectroscopy employs high-
frequency sound waves to probe intramolecular forces in materials such as proteins.22,23
Oscillating compression (and decompression) of the ultrasonic wave causes oscillations in
internal molecular rearrangement. A protein will respond by corresponding compression and
expansion of its volume. In HR-US measurements, attenuation and velocity of ultrasonic
waves were determined. Combined with high precision density measurements, the adiabatic
compressibility of each protein sample was calculated.
Protein compressibility is influenced by both a protein’s internal fluctuations in volume and
its hydration. Because 2-FHis rPA showed greater stability than rPA at pH 5, based on the
EPD characterization results discussed above, measurements of the dynamic properties of
the two proteins were made under this condition. The magnitude of a protein’s apparent
adiabatic compressibility has positive contributions from a protein’s intrinsic volume
fluctuations and negative contributions from the hydration water.24 In Figure 6A, the
apparent adiabatic compressibility values were found to increase with increases in
temperature for both rPA and 2-FHis rPA. 2-FHis rPA displays higher values of adiabatic
compressibility than those of rPA at low temperatures where both proteins exist in their
native states. The negative compressibility, however, suggests a dominant contribution of
hydration water to the experimentally determined compressibility values. The increase in
compressibility with temperature for rPA and 2-FHis rPA therefore could either represent
increases in their intrinsic fluctuations and/or reflect alterations in hydration dynamics
around the protein’s surface due to temperature. Figure 6B shows Trp peak position shifts as
a function of temperature for rPA and 2-FHis rPA when excited at 304 nm (obtained from
red-edge shifts measurements). Excitation of Trp by 304 nm radiation should probe residues
with greater degrees of solvent exposure which are presumably located on the surface of the
protein. The Trp peak position at 10°C was red-shifted for rPA compared to 2-FHis rPA.
This red-shift in peak position could be due to the differences in protein’s tertiary structure
and/or hydration of the surface. The magnitude of the red-shift, however, was greater when
probed with 304 nm compared to 292 nm light (data not shown), suggesting that hydration
contributions to the red-shift are possible. This result along with the compressibility data
(Figure 6A) suggests that the native structure of rPA and 2-FHis rPA may have differences
in their hydration state. Generally, increased dynamic motions, flexibility, void volume
changes and elasticity of proteins will result in higher values of adiabatic compressibility. In
contrast, hydration of proteins, which reduces many of the above processes, will decrease
values of compressibility.
Red-Edge Excitation—Red edge excitation spectroscopy is a fluorescence based
technique used for studying the dynamic properties of proteins. For fluorophores under
conditions where solvent relaxation is not complete (such as the viscous environment
surrounding the buried protein fluorophore), emission spectra shift to longer wavelengths
when excitation wavelengths move to longer wavelengths.25,26 In less viscous
environments, where solvent relaxation is more complete, the magnitude of the red-edge
effect decreases with shifts disappearing in fluid solvents.
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The effect of red-edge excitation on tryptophan fluorescence is quantified here as the shift in
the emission peak when excited at 296, 300, and 304 nm relative to 292 nm. In Figure 6C,
both proteins show clear red shifts at 10°C when the excitation wavelength increases. These
results show that the magnitude of the red-shifts increase as excitation is moved to longer
wavelengths. Similar results were obtained throughout the pre-transition temperature range
(10–20°C for rPA, and 10–30°C for 2-FHis rPA) of their thermal unfolding curves. This
observation suggests that Trp residues located in restricted environments can be sampled
and probed to study the differences in dynamics of such environments in both rPA and 2-
FHis rPA. In Figure 6D, the red-edge excitation shifts, representing the difference in
emission maxima upon red-edge excitation from 292 to 304 nm, are compared for both rPA
and 2-FHis rPA. The magnitude of the shift of rPA is always larger than 2-FHis rPA at low
temperatures prior to thermal structural perturbation. This observation suggests that 2-FHis
rPA displays more dynamic behavior compared to rPA at pH 5. Above the unfolding
temperature, rPA and 2-FHis rPA are prone to aggregate and eventually precipitate out of
solution.
DISCUSSION
In the present study, the physical stability of rPA and 2-FHis rPA was investigated using
spectroscopic and light scattering techniques. Temperature/pH stability profiles of the two
proteins were created and compared. The proteins exhibited similar CD and fluorescence
spectra at low temperatures. The estimated secondary structure contents of the two proteins
are very similar to each other, although 2-FHis rPA displays an increased (about 6.5 %) α-
helix content and a corresponding decrease in β-structure compared to rPA12, as estimated
by the spectral deconvolution software CDNN. Similar thermal unfolding profiles of the two
proteins were also obtained by different techniques at pH 6–8. We conclude that the overall
structural integrity and conformational stability of the protein was not affected by
incorporation of 2-FHis around neural pH values. These results are in agreement with a
previous study of the equilibrium stability of rPA and 2-FHis rPA using urea in which both
proteins showed similar urea denaturation profiles.12
At lower pH values, however, differences in the conformational stability of 2-FHis rPA and
rPA were noted. At pH 5, and to a lesser extent at pH 6, 2-FHis rPA exhibited higher
stability than rPA. This result suggests that 2-FHis incorporation into rPA inhibits pH
dependent unfolding under these mildly acidic pH conditions. Thus, the 2-FHis rPA is much
more thermally stable at lower pH compared to rPA (Table 1).
To better understand why the two rPA proteins demonstrate a stability difference at pH 5,
the dynamic properties of the proteins were compared by red-edge excitation shifts and HR-
US measurements. HR-US measurements suggest that both rPA and 2-FHis rPA may have
differences in their hydration and/or intrinsic fluctuations in which rPA may be more
hydrated than 2-FHis rPA. It is well known that fluorinated compounds exhibit increased
hydrophobicity compared to their hydrogenated counterparts.27 Such increased apolar
character in 2-FHis rPA may cause increased water mobility and less residence times near
such regions.28,29 It is therefore possible that 2-FHis rPA has different hydration
characteristics than rPA but this hypothesis needs further investigation. In addition, red-edge
excitation shift results indicate that 2-FHis rPA has greater dynamic character than rPA at
pH 5. It is often assumed that more dynamic proteins possess less stability.30,31,32 Many
thermostable proteins are, however, quite dynamic, so an increase in thermostability does
not necessarily correlate with a decrease in dynamic behavior.33,34,35,36,37 The relationship
between protein dynamics and stability is not fully understood. The lower extent of
hydration and/or higher dynamic character may increase the stability of the 2-FHis rPA at
lower pH. Solution pH can potentially alter the microenvironmental pH around proteins,
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especially in their hydration layer. If such a phenomenon occurs at lower pH in these
studies, a greater extent of hydration (with higher residence time) may explain the inverse
relationship between the extent of hydration and stability for rPA and 2-FHis rPA. rPA was
earlier determined to be potentially more hydrated than 2-FHis rPA using HR-US studies.
The two methods used in this study both reflect the global dynamic properties of the two
proteins at a specific pH condition. More detailed information about the dynamic properties
of proteins can be obtained by methods such as NMR and H-D exchange mass spectrometry,
which provide information about the local dynamic properties in specific regions of proteins.
This study provides important biophysical information about the effect of 2-FHis on the
conformational stability of rPA in response to environmental stress factors such as pH and
temperature. Our results show that the two proteins have similar stability at pH 7 to 8. The
2-FHis rPA analogue is slightly more stable at pH 6 and shows dramatically increased
stability at pH 4–5. The 2-FHis rPA protein is also more dynamic than rPA at pH 5. These
data provide useful information to better understand the similarities and differences in
physical properties of the two proteins in solution. PA is a primary component in the
currently licensed anthrax vaccine. In comparison, 2-FHis rPA possesses higher thermal
stability under acidic conditions and has the capability to block key steps in its cellular
cytotoxicity. These data suggest that 2-FHis rPA has the potential to for use as an
alternative, more stable antigen in newer, recombinant versions of the anthrax vaccine.
Given the potential need for long term storage of anthrax vaccines as a counter-terrorism
measure, the increased stability of the 2-FHis analogue is an attractive property of this form
of the rPA protein. The pH/temperature stability profile of 2-FHis rPA was generated
through a comprehensive biophysical characterization of the secondary and tertiary
structural integrity, as well aggregation behavior, of the protein. These data can be used as a
starting point for further formulation development of the 2-FHis rPA as a potential anthrax
vaccine or as a potential antitoxin to treat anthrax during the infection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Near- and far-UV CD spectra for rPA and 2-FHis rPA at pH 7 and 10°C. Near and far UV
CD (A, C) and Near-UV CD (B, D) spectra are shown for (A) 0.5 mg/ml rPA at pH 7 and
(B) expanded view of its near-UV region. (C) 0.5 mg/ml 2-FHis rPA at pH 7 and (D)
expanded view of its near-UV region.
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Thermal stability of 2-FHis rPA (0.5 mg/ml at pH 7) as monitored by CD signals at
indicated values (220, 262, 269, 284 and 291 nm) as a function of temperature. Each data
point represents the mean of three independent runs, with error bars showing the standard
deviation.
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Thermal stability of rPA (Figures A and C) and 2-FHis rPA (Figures B and D) at 0.5 mg/ml
as a function of solution pH: (A) and (B) Intrinsic Trp fluorescence emission maximum
(peak position) was monitored; (C) and (D) Optical density at 350 nm was monitored. Each
data point represents the mean of three independent samples, with error bars showing the
standard deviation.
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ANS fluorescence intensity values in the presence (A) rPA and (B) 2-FHis rPA as a function
of temperature and solution pH. Both samples were at 0.5 mg/ml. Each data point represents
the mean of two independent samples, with error bars showing the standard deviation.
Hu et al. Page 15














Empirical phase diagrams (EPDs) of (A) rPA and (B) 2-FHis rPA. The EPD was prepared
from near/far-UV CD, optical density, intrinsic fluorescence (peak position), and extrinsic
(ANS) fluorescence data collected across a pH range from 4 to 8 and a temperature range
from 10°C to 85°C.
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Measurements of dynamic properties of rPA and 2-FHis rPA collected at pH 5. (A)
Ultrasonic measurements of the adiabatic compressibility of the two proteins. (B) Emission
peak positions’ comparison between rPA and 2-FHis rPA at an excitation wavelength of 304
nm. Tryptophanyl dynamics were examined by red-edge excitation shifts of (C) rPA and 2-
FHis rPA based on excitation at 292, 296, 300 and 304 nm. (D) red-edge excitation shifts
compared between excitation at 292 and 304 nm for both proteins. Each data point
represents the mean of three independent runs, with error bars showing the standard
deviation.
Hu et al. Page 17













































































































































































































































































































































































































































J Pharm Sci. Author manuscript; available in PMC 2013 November 01.
